Therapie der Arteriosklerose

Summary

Arteriosclerotic disease develops over the course of several decades. Currently, a number of therapies are at hand to effectively stop this process and avoid complications of arteriosclerosis. Among the non-pharmacologic options, a balanced diet and physical activity predominate. A modern dietary plan offers a variety of tasty servings rich in fresh fruit and vegetables, cereals, fish, and poly-unsaturated fatty acids. The value of regular physical activity is demonstrated by the finding that an increase in exercise capacity („cardiorespiratory fitness”) by only one metabolic equivalent already reduces cardiovascular risk by 20-25 %. Regarding pharmacologic therapy, convincing data are available for cholesterol synthase inhibitors („statins”), some substances which influence the renin-angiotensin system (such as ramipril), and platelet aggregation inhibitors. Statins produce a 20 to 30 % reduction of cardiac death, myocardial infarction, and stroke. In patients with increased cardiovascular risk, the beneficial action of statins is also evident in subjects with low baseline cholesterol values. Apart from the cholesterol-lowering effects, anti-inflammatory and other vasoprotective mechanisms are involved. The angiotensin-converting enzyme inhibitor ramipril has demonstrated that even independent of blood-pressure lowering, cardiovascular events (cardiac death, myocardial infarction, stroke) are substantially reduced in high-risk patients. The effect is in the same order as that of statins. In patients with left-ventricular hypertrophy, the angiotensin-receptor antagonist losartan produces a notable reduction in stroke, independent of its blood-pressure lowering action. Finally, the platelet aggregation inhibitors aspirin and clopidogrel have proven benefit in secondary prevention and, in the case of aspirin, also in primary prevention in cardiovascular high-risk patients. The anti-arteriosclerotic properties of other substances are actively investigated, including calcium channel blockers, betablockers, and novel drug classes. From the medical point of view, a broader use of the well-proven and effective therapies of arteriosclerosis and its complications is clearly warranted.

Literatur

• 1 Albert C H, Campos H, Stampfer M J. et al . Blood levels of long-chain n-3 fatty acids and the risk of sudden death.  N Engl J Med. 2002;  346 1113-1118
• 2 Anand S S, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.  JAMA. 1999;  282 2058-2067
• 3 Anonymus. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.  Lancet. 1999;  354 447-455
• 4 Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
• 5 Blair S N, Kampert J B, Kohl H W 3rd. et al . Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women.  JAMA. 1996;  276 205-210
• 6 Brown B G, Zhao X Q, Chait A. et al . Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.  N Engl J Med. 2001;  345 1583-1592
• 7 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
• 8 Chen Z, Peto R, Collins R. et al . Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.  Br Med J. 1991;  303 276-282
• 9 Cullen P, Assmann G. Primäre und sekundäre Prävention der koronaren Herzkrankheit. Ein Positionspapier der International Task Force for Prevention of Coronary Heart Disease.  Dtsch Med Wochenschr. 2000;  125 881-87
• 10 Dahlöf B, Devereux R B, Kjeldsen S E. et al. The LIFE Study Group . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 11 de Lorgeril M, Salen P, Martin J L, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.  Circulation. 1999;  99 779-785
• 12 Downs J R, Clearfield M, Weis S. et al . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 1615-1622
• 13 Fairfield K M, Fletcher R H. Vitamins for chronic disease prevention in adults.  JAMA. 2002;  287 3116-3126
• 14 Frick M H, Elo O, Haapa K, Heinonen O P. et al . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.  N Engl J Med. 1987;  317 1237-1245
• 15 Gaspoz J M, Coxson P G, Goldman P A. et al . Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.  N Engl J Med. 2002;  346 1800-1806
• 16 Gotto A M, Whitney E, Stein E A. et al . Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).  Circulation. 2000;  101 477-484
• 17 Gotto A M, Farmer J A. Pleiotropic effects of statins: do they matter?.  Curr Opin Lipidol. 2001;  12 391-394
• 18 Hambrecht R, Wolf A, Gielen S. et al . Effect of exercise on coronary endothelial function in patients with coronary artery disease.  N Engl J Med. 2000;  342 454-460
• 19 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
• 20 Heart Outcomes Prevention Evaluation Study Investigators . Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients.  N Engl J Med. 2000;  342 154-160
• 21 Hedblad B, Wikstrand J, Janzon L. et al . Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).  Circulation. 2001;  103 1721-1726
• 22 Hulley S, Grady D, Bush T. et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.  JAMA. 1998;  280 605-613
• 23 Krauss R M, Eckel R H, Howard B. et al . AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association.  Circulation. 2000;  102 2284-2299
• 24 Lauer M S. Clinical practice. Aspirin for primary prevention of coronary events.  N Engl J Med. 2002;  346 1468-1474
• 25 Lee C D, Blair S N, Jackson A S. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men.  Am J Clin Nutr. 1999;  69 373-380
• 26 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med. 1998;  339 1349-1357
• 27 Lonn E, Yusuf S, Dzavik V. et al . SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).  Circulation. 2001;  103 919-95
• 28 Malik I S, Bhatia V K, Kooner J S. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.  Heart. 2001;  85 539-543
• 29 Münzel T, Keaney J F. Are ACE inhibitors a „magic bullet” against oxidative stress?.  Circulation. 2001;  104 1571-1574
• 30 Myers J, Prakash M, Froelicher V. et al . Exercise capacity and mortality among men referred for exercise testing.  N Engl J Med. 2002;  346 793-801
• 31 National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
• 32 Newby L K, Kristinsson A, Bhapkar M V. et al . Early statin initiation and outcomes in patients with acute coronary syndromes.  JAMA. 2002;  287 3087-3095
• 33 Niebauer J, Hambrecht R, Velich T. et al . Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise.  Circulation. 1997;  96 2534-2541
• 34 Pedersen T R, Kjeshus J, Berg K. et al . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 35 Pitt B, Waters D, Brown W V. et al . Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.  N Engl J Med. 1999;  341 70-76
• 36 PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.  Lancet. 2001;  358 1033-1041
• 37 Ridker P M, Rifai N, Clearfield M. et al . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.  N Engl J Med. 2001;  344 1959-1965
• 38 Rimm E B, Stampfer M J. Wine, beer, and spirits - are they really horses of a different color?.  Circulation. 2002;  105 2806-2807
• 39 Roger V L, Jacobsen S J, Pellikka P A. et al . Prognostic value of treadmill exercise testing. A population-based study in Olmsted County, Minnesota.  Circulation. 1998;  98 2836-2841
• 40 Rubins H B, Robins S J, Collins D. et al . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.  N Engl J Med. 1999;  341 410-418
• 41 Sacks F M, Pfeffer M A, Moye L A. et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
• 42 Schartl M, Bocksch W, Koschyk D H. et al . Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.  Circulation. 2001;  104 387-392
• 43 Schwartz G G, Olsson A G, Ezekowitz M D. et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.  JAMA. 2001;  285 1711-1718
• 44 Serruys P W, de Feyter P, Macaya C. et al. Lescol Intervention Prevention Study (LIPS) Investigators . Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  287 3215-3222
• 45 Shepherd J, Cobbe S M, Ford I. et al, for the West of Scotland Coronary Prevention Study Group . Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia.  New Engl J Med. 1995;  333 1301-07
• 46 Smith S C, Blair S N, Bonow R O. et al . AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.  Circulation. 2001;  104 1577-1579
• 47 Stofan J R, DiPietro L, Davis D. et al . Physical activity patterns associated with cardiorespiratory fitness and reduced mortality: the Aerobics Center Longitudinal Study.  Am J Public Health. 1998;  88 1807-1813
• 48 van Hout B A, Simoons M L. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?.  Eur Heart J. 2001;  22 751-761
• 49 Williams J K, Sukhova G K, Herrington D M, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.  J Am Coll Cardiol. 1998;  31 684-691
• 50 Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.  Eur Heart J. 1998;  19 1434-1503
• 51 Writing Group for the Women’s Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
• 52 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med. 2000;  342 145-213